Third-line treatment: A randomized, double-blind, placebo-controlled phase III ALTER-0303 study—Efficacy and safety of anlotinib treatment in patients with refractory advanced NSCLC. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results